The 73 references in paper S. Al-Shukri Kh., M. Rybakova G., A. Lukyanov E., Yu. Ponomareva A., С. Аль-Шукри Х., М. Рыбакова Г., А. Лукьянов Э., Ю. Пономарева А. (2006) “ОНКОМАРКЕРЫ ПРИ ОПУХОЛЯХ ПОЧЕЧНОЙ ПАРЕНХИМЫ // ONCOMARKERS IN TUMORS OF RENAL PARENCHYMA” / spz:neicon:nefr:y:2006:i:1:p:77-85

1
Bostwick DC, Murphy GP Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workgroup. Sem Urol Oncol 1998; 16: 46-52
(check this in PDF content)
2
Аль-Шукри СХ, Ткачук ВН. Опухоли мочеполовых ор­ ганов. СПб.: Питер, 2000; 60-78
(check this in PDF content)
3
Возианов АФ, Романенко АМ, Сайдакова НА и др. Экологический патоморфоз почечноклеточного рака в заг­ рязненных радионуклидами регионах Украины. Журн АМН Украины 2002; (1): 120-131
(check this in PDF content)
4
Brkovic D, Riedash G, Staehler G. Urologe A 1997; 36 (2): 103-108
(check this in PDF content)
5
Hafez KS,Novick AC, Campbell SC. Ibid 1997; 157 (4): 2067-2070
(check this in PDF content)
6
Klein EA, Novick AC. Comprehensive textbook of genitourinary oncology. Baltimore, 1996; 207-217
(check this in PDF content)
7
Lerner SE, Hawkinks CA, Blute ML et al. Parthial nephrectomy. J Urol 1996; 155 (2): 61-66
(check this in PDF content)
8
Степанов ВН, Колпаков ИС, Серегин АВ. Материалы 3-й Всероссийской научн. конф. «Консервативная хирур­ гия при опухоли почки» с участием стран СНГ М., 1999; 151­ 158
(check this in PDF content)
9
Kovacs G, Akhtar M, Beckwith BH. The Heidelberg classification of renal cell tumors. J Pathol 1999; 183: 131-135
(check this in PDF content)
10
Kovacs G. Molecular genetics and diagnosis of renal cell tumors. Urologe A 1999; 38: 433-441
(check this in PDF content)
11
Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15: 68-76
(check this in PDF content)
12
Fuhrman SA, Lasky LS, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663
(check this in PDF content)
13
Hemmerlein B, Markus A, Wehner M et al. Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated m acrophages o f renal cell carcinom as. Cancer Immunol Immunother 2000; 49 (9): 485-492
(check this in PDF content)
14
Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytom etric analysis o f tu m o u r-in filtra tin g lym phocytes in patients with renal cell carcinoma. Cancer Immunol Immunother 2001; 53 (5): 543-548
(check this in PDF content)
15
Shabtai M, Ye H, Frischer Z et al. Increased expression of activation m arkers in renal cell carcinom a in filtra tin g lymphocytes. J Urol 2002; 168 (5): 2216-2219
(check this in PDF content)
16
Zolota V, Tsamandas AC, M elachrinou M et al. Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol 2002; 7(1): 13-17
(check this in PDF content)
17
Huang J, Soffer SZ, Kim ES et al. p53 accumulation in favo ra ble-histo lo gy W ilms tum or is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg 2002; 37 (3): 523-527
(check this in PDF content)
18
Yoshioka K, Nakam ura S.Chrom osom e 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma. Mol Urol 2001; 5 (1): 11-17
(check this in PDF content)
19
Hashimoto H, Sue Y, Saga Y et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2000; 7 (12): 457-463
(check this in PDF content)
20
Rioux-Leclercq N, Turlin B, Bansard J et al. Value of im m unohistochem ical Ki-67 and p53 determ inations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55 (4): 501-505
(check this in PDF content)
21
Haitel A, Wiener HG, Blaschitz U et al. Biologic behavior and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an im m unohistochem ical study correlating grading, staging, and proliferation markers. Cancer 1999; 85 (4): 432-438
(check this in PDF content)
22
Chem eris G, Loktinov A, Rempel A et al. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic m arker for human renal cell tum ors. Virchows Arch 1995; 426 (6): 563-569
(check this in PDF content)
23
Ghanem MA, Van der Kwast TH, Den Hollander JC et al. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. J Cancer 2001;85 (10): 1557-1563
(check this in PDF content)
24
Paraf F, Gogusev J, Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995; 177 (3): 247-252
(check this in PDF content)
25
Chandler D, el-Naggar AK, Brisbay S et al. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994; 25 (8): 789-796
(check this in PDF content)
26
Velickovic M, Delahunt B, M cIver B, Grebe SK. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 200; 15 (5): 479-485
(check this in PDF content)
27
Brenner W, Farber G, Herget T et al. Loss of tum or suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002 May; 99 (1): 53-57
(check this in PDF content)
28
Haitel A, Wiener HG, Neudert B et al. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 2001; 58 (3): 477-481
(check this in PDF content)
29
Yokogi H. Flow cytometric quantitation of the proliferation- associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Cancer 1996;78 (4): 819-826
(check this in PDF content)
30
Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tum or progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118 (1): 47-51
(check this in PDF content)
31
Kraus S, Abel PD, Nachtmann C et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinom a: correlation with prognosis. Hum Pathol 2002; 33 (1): 60-67
(check this in PDF content)
32
Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 1999;80 (1-2): 301-308
(check this in PDF content)
33
Rotter M, Block T, Busch R et al. Expression of HER-2/ neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. J Cancer 1992; 52 (2): 213-217
(check this in PDF content)
34
Fontana LO, Garcia Garcia F, Arcas Martinez Salas I et al. The expression o f p53 and c -e rb -2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival. Arch Esp Urol 2002; 55(7): 792­ 796
(check this in PDF content)
35
Ramp U, Bretschneider U, Ebert T et al. Prognostic im plications of CD95 receptor expression in clear cell renal carcinomas. Hum Pathol 2003; 34 (2): 174-179
(check this in PDF content)
36
Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001; 37 (17): 2199-2203
(check this in PDF content)
37
Dosquet C, Coudert MC, Lepage E et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3 (12 Pt 1): 2451-2458
(check this in PDF content)
38
Inoue K, Kamada M, Slaton JW et al. The prognostic value of angiogenesis and m etastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002; 8 (6): 1863-1870
(check this in PDF content)
39
Alami J, W illiam s BR, Yeger H. Expression and localization of HGF and met in Wilms’ tumours. J Pathol 2002; 196 (1): 76-84
(check this in PDF content)
40
Stumm G, Eberwein S, R ostock-W olf S et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 1996; 69 (1): 17-22
(check this in PDF content)
41
Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003; 56 (2): 107-113
(check this in PDF content)
42
Edgren M, Lennernas B, Larsson A, Kalkner K. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinom a. Anticancer Res 2001; 21(2B): 1423-1429
(check this in PDF content)
43
Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196 (2): 186-193
(check this in PDF content)
44
Ottaiano A, Pisano C, De Chiara A et al. CD40 activation as potential tool in malignant neoplasms. Tumor 2002; 88 (5): 361-366
(check this in PDF content)
45
Ghanem M.A.,Van Der Kwast TN,Sudaryo MK. Expression and prognostic value of CD44 isoform s in nephroblastoma (Wilms tumor). J Urol 2002; 168 (2): 681-686
(check this in PDF content)
46
Miyake H, Eto H, Arakawa S et al. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002; 167 (3): 1282-1287
(check this in PDF content)
47
Rioux-Leclercq N, Epstein JI, Bansard JY et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001; 32 (11): 1209-1215
(check this in PDF content)
48
Li N, Tsuji M, Kanda K et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int 2000; 85 (4): 514-518
(check this in PDF content)
49
Fischer C, Georg C, Kraus S et al. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999; 19 (2C): 1513-1517
(check this in PDF content)
50
Alava E, Panizo A, Sola I et al. CD44v6 expression is related to progression in renal epithelial tum ours. Histopathology 1998; 33 (1): 39-45
(check this in PDF content)
51
Gunthert U, Stauder R, Mayer B et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995; 24: 19-42
(check this in PDF content)
52
G ilcrease MZ, Guzman-Paz M, Niehans G et al.Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999; 86 (11): 2320-2326
(check this in PDF content)
53
Francois C, van Velthoven R, De Lathouwer et al. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 1999; 112 (2): 194-203
(check this in PDF content)
54
Ghanem MA, Van Der Kwast TH, Den Hollander JC et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001; 92 (12): 3120-3129
(check this in PDF content)
55
Ramp U, Jaquet K, Reinecke P et al. Acquisition of TGF- beta 1 resistance: an im portant progression factor in human renal cell carcinoma. Lab Invest 1997; 76 (5): 739-749
(check this in PDF content)
56
Papadopoulos I, W eichert-Jacobsen K, Wacker HH, Sprenger E. Correlation between DNA ploidy, proliferation m arker Ki-67 and early tum or progression in renal cell carcinoma. A prospective study. Eur Urol 1997; 31(1): 49-53
(check this in PDF content)
57
Haitel A, Wiener HG, Migschitz B et al. Proliferating cell nuclear antigen and M IB-1. An alternative to classic prognostic indicators in renal cell carcinomas. Am J Clin Pathol 1997; 107 (2): 229-235
(check this in PDF content)
58
Mitsumori K, Kittleson JM, Itoh N et al. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 2002; 198 (1): 110-114
(check this in PDF content)
59
Diakoumis E, Sourvinos G, Kiaris H et al. Genetic instability in renal cell carcinoma. Eur Urol 1998; 33 (2): 227­ 232
(check this in PDF content)
60
Willers CP, Siebert R, Bardenheuer W et al. Genetic instability of 3p12-p21-specific m icrosatellite sequences in renal cell carcinoma. Br J Urol 1996; 77 (4): 524-529
(check this in PDF content)
61
Terpe HJ, Storkel S, Zimmer U et al. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Br J Urol 1997; 87 (4): 424-429
(check this in PDF content)
62
Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tum or suppressor loci on chrom osom e 9 in prim ary human renal cell carcinomas. Cancer Res 1995; 55 (2): 224-227
(check this in PDF content)
63
Polascik TJ, Cairns P, Epstein JI et al. Distal nephron renal tumors: m icrosatellite allelotype. Cancer Res 1996; 56 (8): 1892-1895
(check this in PDF content)
64
Fujioka T, Hasegawa M, Suzuki Y et al. Telomerase activity in human renal cell carcinoma. Int J Urol 2000; 7 (1): 16-21
(check this in PDF content)
65
Dahse R, Fiedler W, Junker K et al. Telomerase activity and telom ere lengths: alterations in renal cell carcinomas. Kidney Int 1999; 56 (4): 1289-1290
(check this in PDF content)
66
Tuzel E, Kirkali Z, Yorukoglu K et al. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J Urol 2001; 165 (5): 1710-1713
(check this in PDF content)
67
Wang L, Darling J, Zhang JS et al. Incidence of apoptosis and m etallothionein expression in renal cell carcinoma. Oncogene 1998; 16 (5): 635-642
(check this in PDF content)
68
Braun C, Engel M, Seifert M et al. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. Int J Cancer 1999; 84 (1): 6-9
(check this in PDF content)
69
Takenawa J, Kaneko Y, Kishishita M et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Jpn J Cancer Res 1994;89(3): 324-329
(check this in PDF content)
70
Takashi M, Sakata T, Kato K. Use of serum gamma- enolase and aldolase A in combination as markers for renal cell carcinoma. Jpn J Cancer Res 1993; 84 (3): 304-309
(check this in PDF content)
71
Kitamura Y, Watanabe M, Komatsubara S, Sakata Y. Urinary excretion of glycine.prolile dipeptidile aminopeptidase, N-acetyl-beta-D -glucosam inidase, alanine am inopeptidase and low molecular protein in patients with renal cell carcinoma. Hinyokika Kiyo 1990; 36 (5): 535-539
(check this in PDF content)
72
Nakagawa Y, Sirivongs D, Novy MB et al. Nephrocalcin: biosynthesis by human renal carcinom a cells in vitro and in vivo. Cancer Res 1999; 52 (6): 1573-1579
(check this in PDF content)
73
Balitskaia OV, Berdinskikh NK, Kononenko NG. The possibilities of using the free polyam ines of the peripheral blood as biochem ical tum or m arkers in nephroblastom a in children. Vopr Onkol 1992; 38 (6): 674-682 Поступила в редакцию 22.11.2005 г.
(check this in PDF content)